Device Trial Radar · NCT05485935
A Confirmatory Study Confirming Performance of a New Intermittent Catheter
Last checked: Nov 19, 2026Latest source record: Mar 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
73
Actual
Start
Aug 20, 2022
Primary completion
Jan 3, 2023
Study completion Jan 3, 2023
Sponsor
- Lead sponsor
- Coloplast A/SNot on our public-company list
- Sponsor type
- Industry
- First posted
- Aug 3, 2022
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- Male only, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A multi-centre, randomized, controlled crossover design. The total study duration for the individual subject was approximately 9 weeks. The study consisted of four study visits (V0-V3) and two 4-week test periods at home (T1 and T2). Visit 0 and 1 was performed on the same day if subjects allowed. One population included all enrolled subjects who took part in the two test periods in a home setting only (T1 and T2). This constituted the Full Analysis Set (FAS) 1 (N=73)where only endpoints related to dipstick hematuria, catheter perception and quality of life were assessed. A subset of subjects from the FAS1 also took part in two clinic visits (V2 and V3) where endpoints related to bladder emptying and discomfort were assessed. One visit took place in between the two test periods at home (V2) and the other visit took place after the last test period at home (V3) which was also the termination visit. This subset is termed the FAS 2 (N=49).
Conditions
- Urinary Retention
Interventions
Investigational device - intermittent catheter with micro-hole zoneDevice
Intermittent male catheter with micro-hole zone for urinary drainage
Comparator - standard intermittent catheterDevice
SpeediCath Flex, VaPro Pocket, VaPro Plus and VaPro Plus Pocket.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Residual Urine at 1st Flow Stop (HCP-led Catheterization) i.e., Total Catheterisation Volume Minus Volume at 1st Flow-stop, Both Derived From a Catheterisation ProfileTime frame: Immediately after the procedure/catheterization, at second and third clinic visit following 4 weeks of home catheterization
- Number of Flow-stop Episodes (HCP-led Catheterization)Time frame: Immediately after catheterisation, at second and third clinic visit following 4 weeks of home catheterization
Locations
6 sites in 4 countries. Site status is shown where the registry gives one.
Rigshospitalet
Copenhagen, Denmark
Sanos Clinic
Gandrup, North Denmark, Denmark
Hopital Claude Huriez
Lille, France
3 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.